As per DelveInsight’s assessment, The connected drug delivery devices market is largely fueled by the increasing incidence of chronic conditions like diabetes and asthma, along with the expanding adoption of digital health solutions and remote patient monitoring. Additionally, ongoing technological innovations in device design and a surge in product development initiatives by key industry players are further propelling market growth.

DelveInsight’s “Connected Drug Delivery Devices Market Insights, Competitive Landscape, and Market Forecast – 2032” report provides the current and forecast market outlook, forthcoming device innovation, challenges, market drivers and barriers. The report also covers the major emerging products and key Connected Drug Delivery Devices companies actively working in the market.

Explore the future of healthcare innovation with our comprehensive Connected Drug Delivery Devices Market Forecast. Stay ahead in the industry!

https://www.delveinsight.com/report-store/connected-drug-delivery-devices-market

Connected Drug Delivery Devices Overview

Connected Drug Delivery Devices are advanced medical devices integrated with digital technologies such as sensors, Bluetooth, and mobile applications to enhance the administration and monitoring of medications. These devices commonly used for conditions like diabetes, asthma, and chronic diseases include smart inhalers, connected insulin pens, and auto-injectors. They enable real-time data tracking, dose reminders, and remote patient monitoring, improving treatment adherence and clinical outcomes. By integrating with digital health platforms and telemedicine systems, connected drug delivery devices are playing a crucial role in personalized healthcare, supporting both patients and healthcare providers with actionable insights and improved disease management.

Connected Drug Delivery Devices Market Insights

The connected drug delivery devices market is being driven by a combination of key factors working in tandem. The growing prevalence of chronic conditions such as diabetes, asthma, and cardiovascular diseases is increasing the need for solutions that support long-term treatment and enhance patient adherence. At the same time, the expansion of digital health and remote patient monitoring is enabling real-time data tracking and improved patient management. Advancements in device technology, including smart sensors, automated dosing, and mobile app integration, are further enhancing usability and engagement. Moreover, rising product development initiatives by leading companies are broadening the availability of innovative connected devices, thereby accelerating market growth.

DelveInsight Analysis: The global connected drug delivery devices market size is projected to grow significantly, rising from USD 986.91 million in 2024 to USD 5,087.57 million by 2032, registering a strong CAGR of 23.17% during the forecast period.

To know more about why North America is leading the market growth in the Connected Drug Delivery Devices market, get a snapshot of the report Connected Drug Delivery Devices Market Trends

Recent Developments in the Connected Drug Delivery Devices Market Report

• In April 2025, Dexcom received FDA clearance for the G7 15-Day sensor, which boasts extended wear time and enhanced accuracy for diabetes management.

• In March 2025, Enable Injections obtained EU MDR CE-mark for the enFuse Syringe Transfer System, facilitating at-home administration of biologic therapies.

• In December 2024, the US FDA granted tentative approval for Lasix ONYU, a home-use furosemide micropump developed by Gerresheimer’s partner SQ Innovation for treating fluid overload in congestive heart failure patients.

• In January 2024, BIOCORP obtained FDA 510(k) clearance for SoloSmart (a smart cap for Sanofi’s SoloStar insulin pens).

Key Players in the Connected Drug Delivery Devices Market

Some of the key market players operating in the Connected Drug Delivery Devices market include- Findair Sp. z o. o., Adherium, Propeller Health, West Pharmaceutical Services, Inc., BIOCORP, Phillips-Medisize, Merck KGaA, Novo Nordisk A/S, Medtronic, Tandem Diabetes Care, Inc., Ypsomed, Teva Pharmaceutical Industries Ltd., Elcam Medical, Cohero Health, Inc., BD, and others.

To read more about the latest highlights related to Connected Drug Delivery Devices, get a snapshot of the key highlights entailed in the Connected Drug Delivery Devices Market Forecast Report

Market Analysis on the Connected Drug Delivery Devices Market

According to estimates, North America is projected to hold the largest share—approximately 45%—of the connected drug delivery devices market in 2024, driven by its well-established healthcare infrastructure, high adoption of digital health technologies, and increasing focus on patient-centric care. The region’s significant burden of chronic diseases, along with growing awareness around medication adherence and supportive reimbursement frameworks, is further boosting the adoption of advanced solutions such as connected insulin pens, smart inhalers, and wearable injectors.

The competitive landscape of the connected drug delivery devices market is undergoing rapid transformation, driven by a combination of established medtech and pharmaceutical companies as well as emerging digital health startups. The market remains moderately consolidated, with key players such as Medtronic, Insulet, AstraZeneca, Novartis, and Adherium leading growth through strategic partnerships, new product launches, and digital integration initiatives. These companies capitalize on robust R&D capabilities and extensive global distribution networks to strengthen their positions, particularly in segments like connected insulin pens, wearable injectors, and smart inhalers.

Scope of the Connected Drug Delivery Devices Market Report

• Coverage: Global

• Study Period: 2022–2032

• Connected Drug Delivery Devices Market Segmentation By Product Type: Connected Sensors [Connected Inhaler Sensors and Connectable Injection Sensors] and Integrated Connected Devices [Connected Inhaler Devices and Connected Injectable Devices

• Connected Drug Delivery Devices Market Segmentation By Technology: Bluetooth, Near-Field Communication (NFC), and others

• Connected Drug Delivery Devices Market Segmentation By End Users: Hospitals & Clinics, Homecare Settings, and others

• Connected Drug Delivery Devices Market Segmentation By Geography: North America, Europe, Asia-Pacific, and Rest of the World

• Key Connected Drug Delivery Devices Companies: Findair Sp. z o. o., Adherium, Propeller Health, West Pharmaceutical Services, Inc., BIOCORP, Phillips-Medisize, Merck KGaA, Novo Nordisk A/S, Medtronic, Tandem Diabetes Care, Inc., Ypsomed, Teva Pharmaceutical Industries Ltd., Elcam Medical, Cohero Health, Inc., BD, and others

• Porter’s Five Forces Analysis, Product Profiles, Case Studies, KOL’s Views, Analyst’s View

Which MedTech key players in the Connected Drug Delivery Devices market are set to emerge as the trendsetter explore @ Connected Drug Delivery Devices Manufacturer

Table of Contents

About DelveInsight

DelveInsight is a leading Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Gaurav Bora
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/